Lee Ainslie Adagio Therapeutics, Inc. Transaction History
Maverick Capital LTD
- $5.84 Billion
- Q2 2025
A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Maverick Capital LTD holds 10,229,118 shares of ADGI stock, worth $33.9 Million. This represents 0.58% of its overall portfolio holdings.
Number of Shares
10,229,118
Previous 10,958,572
6.66%
Holding current value
$33.9 Million
Previous $36.3 Million
6.66%
% of portfolio
0.58%
Previous 0.71%
Shares
7 transactions
Others Institutions Holding ADGI
# of Institutions
68Shares Held
63.2MCall Options Held
13.9KPut Options Held
0-
Mithril Ii Gp LP Austin, TX11.2MShares$37.2 Million27.49% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million39.04% of portfolio
-
Deep Track Capital, LP Greenwich, CT8.59MShares$28.4 Million1.01% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.93MShares$13 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...